Form 4: Axogen EVP & General Counsel Marc Began Reports Acquisition of 55,000 Restricted Stock Units

Axogen's EVP & General Counsel, Marc Began, reports the acquisition of 55,000 restricted stock units (RSUs) in a recent SEC filing.

Summary

• On March 25, 2025, Marc Began, EVP & General Counsel of Axogen, Inc., acquired 55,000 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock.
• The RSUs will vest over a four-year period, with 50% vesting on March 25, 2027, and an additional 25% vesting each 12 months thereafter until March 25, 2029.
• Vested shares will be delivered to Mr. Began upon each vesting date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral positive.

Positives

• The grant of RSUs aligns Mr. Began's interests with those of Axogen's shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The vesting schedule indicates a long-term commitment from Mr. Began to Axogen.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives.

Stakeholder Impact

• The RSU grant aligns management's interests with shareholders, potentially leading to increased shareholder value.

Key Dates

Keywords

Axogen, Marc Began, Restricted Stock Units, RSUs, SEC Form 4, Beneficial Ownership, Vesting, Equity Compensation